Clinical Trials Logo

Transarterial Chemoembolization clinical trials

View clinical trials related to Transarterial Chemoembolization.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04997850 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma Non-resectable

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

Start date: May 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

We adopted the prospective cohort study to compare the safety and efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody in the treatment of advanced unresectable liver cancer.The purposes of our study include:1. Primary objective: To compare the safety and efficacy of TACE combined with Lenvatinib and PD-1 antibody versus TACE alone in the conversion-resection of patients with advanced unresectable hepatocellular carcinoma.2. Secondary objective: To compare the long-term outcome of TACE combined with Lenvatinib and PD-1 antibody versus TACE alone for patients with advanced unresectable hepatocellular carcinoma.